ZBTB37 Inhibitors
ZBTB37 Inhibitors encompass a series of chemical entities that attenuate the activity of the ZBTB37 protein by interfering with specific intracellular signaling cascades and transcriptional regulation mechanisms. Compounds such as PD 98059 and U0126, which are selective inhibitors of MEK, act to suppress the MAPK/ERK pathway, thus potentially reducing the activity of transcription factors that govern the expression of ZBTB37. In a similar vein, LY 294002 and Wortmannin, both inhibitors of PI3K, disrupt the PI3K/Akt signaling pathway, which is integral to the regulation of various transcription factors; their inhibition can lead to a decrease in the transcriptional activity of genes regulated by this pathway, including ZBTB37. Additionally, SB 203580 targets p38 MAP kinase, another component of the MAPK pathway, which upon inhibition could result in diminished transcription factor activation and subsequent downregulation of ZBTB37 expression.
Trichostatin A and BIX01294 operate by altering the epigenetic landscape, with Trichostatin A inhibiting histone deacetylases and BIX01294 targeting G9a histone methyltransferase, both resulting in chromatin modifications that can lead to a decrease in the transcription of genes like ZBTB37. The DNA methyltransferase inhibitor 5-Azacytidine may also contribute to this effect by changing the methylation status of gene promoters. Additionally, Rapamycin, through mTOR inhibition, and SP600125, a JNK inhibitor, may indirectly lead to reduced expression of ZBTB37 by impacting protein synthesis and AP-1 transcriptional activity, respectively. Curcumin's suppression of the NF-κB signaling pathway and Cyclopamine's inhibition of the Hedgehog pathway further exemplify the diverse mechanisms by which chemical compounds can diminish the functional activity of ZBTB37 without directly interacting with the protein itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which functions upstream of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can reduce ERK pathway signaling, which may lead to diminished activity of transcription factors that regulate ZBTB37 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it disrupts the PI3K/Akt signaling pathway, which is crucial for many cellular processes, including transcription. This disruption can decrease the activity of transcription factors that are involved in the regulation of ZBTB37 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase, which is part of the MAPK pathway. By inhibiting p38, SB 203580 can lead to reduced activation of transcription factors that modulate the expression of genes like ZBTB37. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It affects the acetylation state of histones, which can lead to changes in chromatin structure and subsequently diminish the transcription of certain genes, potentially including ZBTB37. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. By inhibiting DNA methylation, it can cause the reactivation of silenced genes; however, it can also lead to decreased expression of other genes like ZBTB37 by altering the methylation status of their promoters. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, similar to PD98059, and suppresses the MAPK/ERK pathway. This suppression can lead to a decrease in the activity of ERK-regulated transcription factors, potentially diminishing ZBTB37 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a potent mTOR inhibitor that affects the mTOR signaling pathway, which is important for cell growth and proliferation. Inhibition of mTOR can lead to decreased protein synthesis and may negatively impact the expression of proteins that are under tight regulatory control, like ZBTB37. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. Inhibiting JNK activity can lead to reduced transcriptional activity of AP-1, a transcription factor that could regulate the expression of genes like ZBTB37. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. It leads to disruption of the PI3K/Akt pathway, potentially reducing the activity of transcription factors that control the expression of genes such as ZBTB37. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX01294 is an inhibitor of G9a histone methyltransferase, which methylates histone H3. By inhibiting G9a, BIX 01294 can alter chromatin structure and diminish the transcriptional activity of genes, possibly including ZBTB37. | ||||||